MSD has received the US Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), along with paclitaxel, with or without bevacizumab, for ovarian cancer.
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and Niemann-Pick type C rare diseases.
Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous system (CNS) and autoimmune diseases.
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence application (BLA) for RGX-121 (clemidsogene lanparvovec) to treat mucopolysaccharidosis II (MPS II), also called Hunter syndrome.
Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.
Innovent Biologics and Eli Lilly and Company have entered a strategic collaboration agreement to accelerate the global development of new medicines in the fields of oncology and immunology.
Novartis has commenced construction on its new global biomedical research centre in San Diego, California, US, aimed at expanding its drug discovery capabilities.
Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism.
PrimeGen US and DT Cloud Star Acquisition have entered a definitive business combination agreement at an implied equity value of around $1.5bn.
Relay Therapeutics has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for zovegalisib (RLY-2608), along with fulvestrant, for human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.